STAAR Surgical Generates Cash From Operations During Seco...(were $1.4 million or $0.04 per share. F...),Health

Date:8/3/2009

were $1.4 million or $0.04 per share. For the six months ended July 3, 2009, the net loss was $2.8 million, or $0.09 per share, compared with a net loss of $11.5 million, or $0.39 per share for the first half of 2008. During the first six months of 2009, non-cash charges were $2.9 million or $0.09 per share. Purchase accounting charges associated with the acquisition of STAAR Japan impacting the first six months of 2008 were $5.4 million or $0.18 per share.

On July 3, 2009, the Company reported cash, cash equivalents and restricted cash of $13.1 million compared with $5.2 million at the end of 2008 and $3.7 million at the end of the first quarter of 2009. During the quarter, the Company raised $8.6 million to fund a deposit as a guarantee for the judgment in the Parallax case pending appeal.

Conference Call

The Company will host a conference call and webcast on Monday, August 3, 2009 at 8:30 a.m. Eastern Time to discuss the Company's second quarter and current corporate developments. The dial-in number for the conference call is 877-941-1848 for domestic participants and 480-629-9722 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4117561#. To access the live webcast of the call, go to STAAR Surgical's website at www.staar.com. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing prop
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
5. Richard A. Meier Appointed to STAAR Surgical Board of Directors
6. STAAR Surgical Completes Common Stock Offering
7. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
8. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
9. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
10. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
11. STAAR Surgical Reports 33% Third Quarter Revenue Growth